

## DAFTAR PUSTAKA

1. Sing G. Pterigium and Its Surgery. In Foster CS, Azar DT, Dohlman CH, editors. Smolin and Thoft' *The Cornea Scientific Foundations and Clinical Practice*. 4<sup>th</sup> ed. Philadelphia: Lippincott William & Wilkins. 2005. pp. 999 – 1014.
2. Tan DTH. Pterygium. In: Edward J.Holland, Mark J.Mannis, *Ocular Surface Disease Medical and Surgical Management*: 9<sup>th</sup> ed ( II ) New York. Springer-Verlag, 2002. pp. 65 – 89.
3. Solomon AS. Pterygium, *Br J Ophthalmol* 2006; 90: pp. 665-666.
4. Waller SG, Adamis AP, Pterygium in *Duane's Clinical Ophthalmology*, 35 (6), Lippincott William & Wilkin, 2004.
5. Gazzard G, Saw S-M, Farook M, Koh D, Widjaja D, Chia S-E, Hong C-Y, Tan DTH, Pterygium in Indonesia: Prevalence, Severity and Risk Factors. In *Br.J.Ophthalmol* 2002; 86 (12): pp. 1341-1346.
6. Lu Peng, Chen Ming Xiao, Prevalence and Risk Factors of Pterygium. *Int J Ophthalmol* 2009; 2 (1): pp. 82-85.
7. Lutra R, 2001, Nemesure BB, Wu SY, Xie SH, Leske MC, Frequency and Risk Factor for Pterygium in the Barbados Eye Study. *Archives of Ophthalmology* 2001; 119 (12): pp. 827-32.
8. Hill JC, Maske R. Pathogenesis of Pterygium. *Eye* 1989; 3: pp. 218-226.
9. Shintya D, Syawal R, Sirajuddin J, Syamsu N. The Profile of Tears Mucin Layers and Impression Cytology in Pterygium Patients. *Jurnal Oftalmologi Indonesia* 2010; 7 (4): pp. 139-143.
10. Erry, Mulyani UA, Susilowati D. Distribusi dan Karakteristik Pterigium di Indonesia. In *Buletin Penelitian Sistem Kesehatan* 2011; 14: pp. 84-89.
11. Dinas Kesehatan Propinsi Sumatera Barat, Rumah Sakit M Djamil, Fakultas Kedokteran Universitas Andalas, *Laporan Survei Kebutaan dan Kesehatan Mata di Sumatera barat Tahun 2008*.
12. Besharati MR, Manaviat MR, Souzani A. Subconjunctival Bevacizumab Injection in Treatment of Pterygium. *Acta Medica Iranica* 2011; 49 (3): pp. 179-183.

13. Omar R, Rimsha S, Waseem R, Arshad R, Shahzada BS. Role of Subconjunctival Bevacizumab in Treatment of Pterygium. *Pak J Ophthalmol* 2012;28 (3): pp.132-135
14. Felipe AF, Siong RLB, S Harvey. Subconjunctival Injection of Bevacizumab for Treatment of Pterigium. *Philippine Journal of Ophthalmology* 2009; 34 (1): pp. 44-50.
15. Aspiotis M, Tsanou E, Gorezis S, Loachim E, Skyrilas A, Stefaniotou M, Mitsi VM. Angiogenesis in Pterygium: Study of Microvessel Density, Vascular Endothelial Growth Factor and Thrombospondin-1. *Eye* 2007; 21: pp. 1095-1101.
16. Detorakis ET, Zaravinos A, Spandidos DA. Growth Factor Expressions in Ophthalmic Pterygia and Normal Conjunctiva. *International Journal Of Molekuler Medicine* 2010; 25: pp. 513-516.
17. Mauro J, Foster CS. Pterygia: Pathogenesis and the Role of Subconjunctival Bevacizumab in Treatment. *Seminar in Ophthalmology* 2009; 24: pp. 130-139.
18. Hurmeric V, Vaddavalli P, Galor A, Perez VL, Roman JS, Yoo SH . Single and Multiple Injections of Subconjunctiva Ranibizumab for Early, Recurrent Pterigium. *Clinical Ophthalmology* 2013; 7: pp.467-473.
19. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer. *Rev Drug Disc* 2004; 3: pp. 391-400.
20. Collet L, Larson TA, Bakri SJ. Bevacizumab for Ophthalmic Disease Ophthalmic. *US Ophthalmic Review* 2007; pp. 20-24.
21. Tafti MRF, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of Intralesional Bevacizumab Injection in Decreasing Pterigium Size. *Cornea* 2011; 30: pp. 127-129.
22. Crick RP, Khaw PT, *Practical Anatomy and Physiology of the Eye and Orbit*, in: A Textbook of Clinical Ophthalmology, A Practical Guide to Disorder of the Eyes and Their Management, Chapter 2, World Scientific, New Jersey 2003; pp 5-43.

23. Tsubota K, Tseng SCG, Nordlund ML, *Anatomy and Physiology of the Ocular Surface*. In :Holland, Manis Mj ed. *Ocular Surface Disease*. Newyork : Springer-verlag; 2002; pp 3-15.
24. Tan CS, Lim TH, Koh WP, Liew GC, Hoh ST, Tan CC. Epidemiology of Pterygium on a Tropical Island in the Riau Archipelago. *Eye (Lond)*. 2006; 20 (8): pp. 908-912.
25. Moran D.J, Hollows F.C, Pterygium and Ultraviolet Radiations: A Positive Correlations. *British Journal Ophthalmology* 1984; 68: pp. 343-346.
26. Lee SB, Slomovic A. Pterygium- An Update on Current Concepts and Treatment Modalities. *Ophthalmology Rounds* 2004; 2: pp. 5-11.
27. Coroneo M. Ultraviolet Radiation and the Anterior Eye, *Eye & Contact Lens* 2011.
28. Detorakis ET, Spandidos DA. Pathogenetic Mechanisms and Treatment Options for Ophthalmic Pterygium: Trends and Perspectives (Review). *International Journal of Molecular Medicine* 2009; 23: pp. 439-447.
29. Cameron EM, Hystology of Pterygium: An Electron Microscopic Study. *British Journal Ophthalmology* 1983; 67: pp. 604-608.
30. Girilamo ND, Kumar RK, Coroneo MT, Wakefield D. UVB-Mediated Inductions of Interleukin-6 and Interleukin-8 in Pterygia and Cultured Human Pterygium Epithelial Cells. *Investigative Ophthalmology & Visual Science* 2002; 43: pp. 3430-3437.
31. Chui J, Coroneo MT, Tat LT, Crouch R, Wakefield D, Girilamo ND. Ophthalmic Pterygium: A Stem Cell Disorder with Premalignant Features. *Am J Pathol* 2011; 178: pp. 817-827.
32. Anguria P, Kitinya J, Ntuli S, Carmichael T. The Role of Heredity in Pterygium Development. *Int J Ophthalmol* 2014;7(3): pp. 563-573.
33. Chui J, Girilamo ND, Wakefield D, Coroneo MT. The Pathogenesis of Pterygium: Current Concepts and Their Therapeutic Implications. *The Ocular Surface* 2008; 6: pp. 24-39.

34. Bradley J.C, Yang W, Bradley RH, Reid TW, Schwab I.R. The Science of Pterygium. *British Journal Ophthalmology* 2010; 94: pp. 815-20.
35. Tradjutrismo N, Pterygium: Degeneration, Exuberant Wound Healing or Benign Neoplasma? *Univ Med* 2009; 28: pp. 179-187.
36. Dzunic B, Jovanovic P, Veselinovic, Petrovic A, Stefanovic I, Kovacevic I. Analysis of Pathohistological Characteristics of Pterygium. *Bosnian Journal of Basic Medical Sciences* 2010; 10 (4): pp. 307-313.
37. Dilek FH, Ozturk F, Aktepe F, Ermis S, Mutlu FM . Mast Cells and Angiogenesis in Primary and Recurrent Pterygia. *Turkish Journal of Pathology* 2007; 23 (3): pp. 132-136.
38. Livezeanu C, Craioiu MM, Manescu R, Mocanu C, Craioiu S. Angiogenesis in the Pathogenesis of Pterygium. *Rom J Morphol Embryol* 2011; 52 (3): pp. 837-844.
39. Seifert P, Sekundo W. Capillaries in the Epithelium of Pterygium. *Brithis Journal of Ophthalmology* 1998; 82: pp.77-81.
40. Buratto L, Phillips RL, Carito G. *Pterygium Surgery*. Slack Incorporated. New Jersey. USA 2000
41. Aminlari A, Sing R, Liang D. Management of Pterygium. *Ophthalmic Pearls Cornea. Eynet.* (online) 2010: pp 37-38. Tersedia di <http://www.aaopt.org/publications.eyenet/2010>.
42. Janson BJ, Sikder S. Surgical Management of Pterygium. *The Ocular Surface* 2014; 12 (2): pp. 112-119.
43. Raju V.K, Chandra Abhishek, Rahul. Management of Pterygium-a Brief Review. *Kerala Journal Ophthalmology* 2008; 20 (1): pp. 63-65.
44. Alhammami H, Farhood Q, Shuber H. Subconjunctival Bevacizumab Injections in Treatment Recurrent Pterygium. *J Clin Exp Ophthalmol* 2013; 4: pp. 1-4.
45. Fisher JP. Pterygium.Follow Up. Diakses dari <http://emedicine.medscape.com> .2013:1-4
46. Mahar PS, Hanfi AN, Khan A. Angiogenesis and Role of Anti-VEGF Theraphy. *Pak J Ophthalmol* 2009; 25 (3): pp. 169-173.

47. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K. Pharmacokinetics of Bevacizumab After Topical, Subconjunctival and Intravitreal Administration in Rabbit. *IOVS* 2009; 50: pp. 4807-4813.
48. Dastjerdi MH, Sadrai Z, Saban DR, Qiang Zhang, Dana R. Corneal Penetration of Topical and Subconjunctival Bevacizumab. *IOVS* 2011; 52 (12): pp. 8718-8723.
49. Section 21 Ophthalmology Preparations Bevacizumab-Addition diakses dari [http://www.who.int/selection\\_medicines/committees/expert](http://www.who.int/selection_medicines/committees/expert).
50. Chen Wei-Li, Lin CT, Lin NT, Tu IH, Li JW, Chow LP. Subconjunctival Injections of Bevacizumab (Avastin) on Corneal Neovascularization in Different Rabbit Models of Corneal Angiogenesis. *IOVS* 2009; 50 (4): pp.1659-1665.
51. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ, Absence of Histologic Retinal Toxicity of Intravitreal Bevacizumab in a Rabbit Model. *AJO* 2006; 142 (5): pp. 855-859.
52. Bhatti N, Qidwai U, Fawad U, Hussain M, Rehman AU, Hasan MU. Side Effects and Effectiveness of Subconjunctival Bevacizumab Injections in Patients with Corneal Neovascularization. *Pak J Ophthalmol* 2012; 28 (1): pp. 33-37.
53. Dahlan M.S. Besar Sampel dan Cara Pengambilan Sampel. Edisi ke-3. Jakarta: Salemba Medika 2012; pp.19-23.
54. Dahlan M.S..Statistik Untuk Kedokteran dan Kesehatan . Edisi ke-5. Jakarta: Salemba Medika 2012 pp.120-166
55. Ha SW, Park JH, Shin IH, Kim KK, Clinical Analysis of Risk Factors Contributing to Recurrence of Pterygium after Excision and Graft Surgery. *Int J.Ophthalmol* 2015; 8 (3): pp. 522-527.
56. Julita, *Perbandingan Densitas Sel goblet Konyungtiva pada Mata Pterigium dan Non Pterigium dengan Pemeriksaan Sitologi Impresi*. Tesis. PPDS Ilmu Kesehatan Mata FK-UNAND; 2014.
57. Yusardi R, *Perbandingan Hasil Keratometri Sebelum dan Sesudah Eksisi Pterigium Dihubungkan dengan Ukuran Pterigium*. Tesis. PPDS Ilmu Kesehatan Mata FK-UNAND; 2010.

58. Meseret A, Bejiga A, Ayalew M. Prevalence of Pterygium in Rural Community of Meskan District, Souther Ethiopia. Original Article. *Ethiop.J.Health Dev* 2008; 22 (2): pp. 191-194.
59. Stival LRS, Lago AM, Figueiredo MNFC, Bittar RHG, Machado ML, Junior JJN. Efficacy and Savety of Subconjunctival Bevacizumab for Recurrent Pterygium. *Arq Bras Oftalmol* 2014;77 (1): pp. 4-7.
60. Parrikh SS, Mehta HH, Desai BI. Advances in Development of Bevacizumab, a Humanized Anti-Angiogenic Therapeutic Monoclonal Antibody Targeting VEGF in Cancer Cells. *Int J Pharm Biomed Sci* 2012; 3 (4): pp. 155-163.
61. Jain RK. Molecular Regulation of Vessel Maturation. *Nature Medicine* 2003; 9: pp. 685 – 693.
62. Park YM, Kim CD, Lee JS. Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Prymary and Recurrent Pterygium. *Korean J Physiol Pharmacol* 2015; 19: pp. 357-363.

